Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?

Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?

Despite the availability of a lot of effective disease-modifying drugs, multiple sclerosis (MS) (in particular the progressive forms) still represents an important unmet medical need, because of issues in terms of effectiveness, duration of response, safety, and patient compliance. An increasing bod...

Full description

Bibliographic Details
Main Authors: Serena Brancati, Lucia Gozzo, Laura Longo, Daniela Cristina Vitale, Filippo Drago
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
rituximab
off-label
regulatory issue
disease-modifying drugs
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.661882/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.661882/full

Similar Items